DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: TNBC, Triple Negative Breast Cancer

Interventions: Drug: Ivonescimab

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: Fudan University

Target Recruit Count: 53

Registration Number: NCT06977542

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Platinum Resistant Ovarian Cancer

Interventions: Drug: Utidelone Capsules
Drug: Fruquintinib Capsules

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Fudan University

Target Recruit Count: 35

Registration Number: NCT06973421

Locations: 🇨🇳
Fudan University Shanghai Cancer Cente, Shanghai, Shanghai, China

A Prospective, Single-Arm, Open-Label, Single-Center Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib in Subjects With NRAS-Mutant Locally Advanced or Metastatic Thyroid Cancer

Phase 2

Not yet recruiting

Conditions: Progressive Locally Advanced or Metastatic Radioactive Iodine Refractory NRAS Mutant Differentiated Thyroid Cancer
Locally Advanced or Metastatic NRAS Mutant Differentiated, Undifferentiated Thyroid Cancer

Interventions: Drug: Tunlametinib
Drug: Tunlametinib plus PD-1

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT06970353

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

Phase 2

Recruiting

Conditions: Melanoma of Skin
Acral Melanoma
Stage II Melanoma

Interventions: Drug: Toripalimab combined with Endostar

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 58

Registration Number: NCT06965231

Locations: 🇨🇳
Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Cancer center, Shanghai 411 hospital, China RongTong Medical Healthcare Group Co.Ltd./411 Hospital, Shanghai University, Shanghai, Shanghai, China
🇨🇳
Department of Surgical Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, Shanghai, China

and more 1 locations

A Real World Study of Sacituzumab Govitecan

Recruiting

Conditions: Breast Cancer Metastatic
Treatment Outcome

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06966141

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Phase 1

Not yet recruiting

Conditions: Natural Killer/T-cell Lymphoma
Relapsed or Refractory Lymphoma Including ENKL

Interventions: Drug: tislezumab
Drug: golidocitinib
Drug: Selinexor

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT06966154

Locations: 🇨🇳
Dept of lymphoma and medical oncology, Shanghai Cancer Center, Shanghai, Shangai, China

Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

Not Applicable

Not yet recruiting

Conditions: Breast Carcinoma
Patient Education
Perioperative Care
Psychological Intervention

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-13

Lead Sponsor: Fudan University

Target Recruit Count: 1138

Registration Number: NCT06965556

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Phase 3

Recruiting

Conditions: Esophageal Carcinoma
Radiotherapy
Immunotherapy

Interventions: Drug: PD-1 inhibitor
Radiation: Unlimited radiotherapy
Radiation: TDLN-sparing radiotherapy

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Fudan University

Target Recruit Count: 452

Registration Number: NCT06964568

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Phase 3

Not yet recruiting

Conditions: Laryngeal Carcinoma
Hypopharyngeal Carcinoma

Interventions: Drug: Neoadjuvant Chemotherapy (NACT)
Drug: Neoadjuvant and maintenance Tislelizumab
Radiation: Concurrent chemo-radiotherapy (CCRT)
Procedure: Surgery and adjuvant (chemo-)radiotherapy

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-08

Lead Sponsor: Fudan University

Target Recruit Count: 168

Registration Number: NCT06957938

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer

Not Applicable

Not yet recruiting

Conditions: Rectal Cancer

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: Fudan University

Target Recruit Count: 1596

Registration Number: NCT06956976

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy